Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CardioGenesis adds platelet prep tech to portfolio:

This article was originally published in Clinica

Executive Summary

CardioGenesis plans to launch this month a product for preparing autologous platelet rich plasma in point of care (POC) settings. The CelleratOR, which represents the firm's first new product beyond laser myocardial revascularisation devices, is designed for use in surgical suites. It consists of a small centrifuge system and proprietary disposables to prepare the platelet concentrate from the patient's blood sample; the concentration level can be determined by the physician at the time of preparation. Compared with competitive systems, the Foothill Ranch, California firm claims that CelleratOR provides the advantage of scalability. In a separate announcement, CardioGenesis said it had gained US market approval for its SolarGen 2100s product, an advanced laser console for performing surgical heart laser therapy.

You may also be interested in...



Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.

Topics

UsernamePublicRestriction

Register

MT053909

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel